N
ADPT icon

Natixis’s Adaptive Biotechnologies ADPT Stock Holding History

Natixis’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-47,600
Closed -$712K – 1113
2025
Q3 		$712K Buy
+47,600
New +$580K ﹤0.01% 731
2022
Q2 		– Sell
-157,474
Closed -$2.19M – 1140
2022
Q1 		$2.19M Buy
+157,474
New +$2.48M 0.01% 733
2021
Q4 		– Sell
-5,905
Closed -$201K – 1213
2021
Q3 		$201K Sell
5,905
-47
-0.8% -$1.7K ﹤0.01% 1148
2021
Q2 		$243K Sell
5,952
-62,122
-91% -$2.42M ﹤0.01% 800
2021
Q1 		$2.74M Buy
68,074
+41,874
+160% +$2.27M 0.01% 628
2020
Q4 		$1.55M Sell
26,200
-36,380
-58% -$1.88M 0.01% 729
2020
Q3 		$3.04M Buy
+62,580
New +$2.63M 0.02% 354

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Natixis's ADPT Position: Q4 2025 in Review

Natixis sold out of Adaptive Biotechnologies (ADPT) in Q4 2025, closing a stake of 47,600 shares — an estimated $712K sold.

Natixis first reported a position in ADPT in Q3 2020 and held it in 7 quarters. The position peaked at $3.04M in Q3 2020. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • Natixis reported no remaining Adaptive Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Natixis sold 47,600 Adaptive Biotechnologies shares in Q4 2025, an estimated $712K.
  • Natixis first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 7 quarters.
  • Natixis's Adaptive Biotechnologies position peaked at $3.04M in Q3 2020.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Natixis's 13F filing for Q4 2025, filed 13 Feb 2026.